General Information
The combination of valsartan and sacubitril constitutes a novel strategy to reduce the risk of death and hospitalization due to heart failure. It is used in patients with chronic heart failure and reduced ejection fraction for almost all severity levels of heart failure (except for the lowest, level I, by New York Heart Association Functional Classification). Ejection fraction is a measurement for assessing the heart’s ability to pump out blood and for diagnosing and monitoring heart failure.
About the API
- Japan DMF
- Korea DMF
- US DMF
Updates About Valsartan Sacubitril
The information detailed herein, including that with regard to active pharmaceutical ingredients , their use in treatments and possible mechanism(s) of action, was all obtained from public sources.
For more information on our services and products – including product suitability, intended uses and current availability – please contact Teva api Customer Service. CAS Registry Number is a Registered Trademark of the American Chemical Society. This webpage and any reference to the above product is to be read within the meaning and terms of the Legal Notes.